Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
申请人:Bristol-Myers Squibb Company
公开号:US07125870B2
公开(公告)日:2006-10-24
The present application describes novel isoxazoline of formula I or II:
or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), or a combination thereof.
本申请描述了一种新的异噁唑烷,其化学式为I或II:
其中A,R1,R2,R3,R4,Z,U,X,Y,Za和n在本说明书中有定义,并且其药物可接受的盐或前药形式,该异噁唑烷可作为基质金属蛋白酶(MMP),TNF-α转化酶(TACE)或两者的抑制剂。